A patient I’ve been following for three years — treatment-resistant MDD, two failed antidepressant trials, one failed esketamine course — finally agreed to consider a convulsive therapy. His exact words: “I’ll do anything except ECT. My uncle had it and forgot his grandchildren’s names for six months.” That objection is not anecdotal. In my practice, it is the single most consistent barrier to convulsive therapy referral, and it is grounded in enough real-world experience that dismissing it as fear-based doesn’t hold up clinically.
The CREST-MST trial, published in Lancet Psychiatry in April 2026, just handed clinicians something to say back.
What the Data Actually Show
The CREST-MST trial is a randomized, double-blind, non-inferiority study conducted across sites in Canada and the United States, comparing magnetic seizure therapy directly against right unilateral ultra-brief electroconvulsive therapy — currently considered the cognitive-sparing gold standard within the ECT family. The headline result: MST achieved non-inferior remission rates. Not a trend. Not a signal. Non-inferiority confirmed in a properly powered, blinded, multi-site design.
The cognitive safety data are where the trial becomes operationally important. MST demonstrated a more favorable cognitive profile than RUL-UB ECT — the version of ECT specifically optimized to reduce memory burden. That comparison matters because the field has spent decades arguing that right unilateral ultra-brief pulse ECT represents the least cognitively toxic form of electrical convulsive therapy available. MST outperformed it on that dimension while matching it on remission.
The mechanism explains why. MST uses transcranial magnetic stimulation to induce a seizure, allowing far more focal targeting of prefrontal cortex compared to the broader electrical field spread in ECT. Hippocampal structures — central to autobiographical and anterograde memory — receive substantially less direct stimulation. The CREST-MST result is consistent with that mechanistic prediction. What’s new is the confirmatory, blinded, controlled evidence at scale to support it.
The Recruitment Problem This Solves
Having treated thousands of patients with treatment-resistant depression across both in-person and telehealth settings, I can tell you that ECT refusal is not a fringe phenomenon. Published estimates suggest somewhere between 30 and 50 percent of patients who meet clinical criteria for ECT either decline it outright or disengage from care rather than accept referral. That refusal pool is not a lost cause — it is a patient population that has already been filtered for severity and treatment failure, and that is exactly the population convulsive therapy trials need.
The CREST-MST authors explicitly note that MST warrants consideration as a first-line convulsive therapy, particularly for patients who refuse RUL-UB ECT. From a site recruitment perspective, that framing opens an enrollment pathway that has historically been closed. Patients who screen out of ECT trials due to refusal — and who are consequently excluded from the most severely treatment-resistant depression research — become eligible candidates under an MST protocol.
Protocol design will need to catch up. Most current TRD trial eligibility criteria define prior convulsive therapy exposure as a binary: had ECT or did not. The CREST-MST data now create the clinical rationale for a third category — ECT-refused, MST-eligible — that sponsors designing next-generation neuromodulation studies should be building into their inclusion logic from the ground up.
What the Field Hasn’t Resolved Yet
Non-inferiority on remission and superiority on cognitive safety are necessary conditions for clinical adoption. They are not sufficient ones.
MST requires specialized equipment that is not yet widely deployed — the magnetic stimulation systems capable of inducing a therapeutic seizure are distinct from standard TMS devices, and credentialing and training infrastructure at most academic medical centers remains thin. Scaling beyond the research setting will require both capital investment and the kind of practitioner training pipeline that ECT, after decades, now takes for granted. The CREST-MST trial establishes the efficacy signal. Building the delivery infrastructure is a separate problem, and sponsors entering this space should price that reality into their site selection strategy.
The cognitive outcome data also deserve longitudinal scrutiny. The trial’s favorable MST profile is compelling, but the durability of both remission and cognitive protection across maintenance treatment sequences — the real-world pattern for most TRD patients — is the next evidentiary gap to close.
I’ll be watching for whether any sponsor uses the CREST-MST publication as the inflection point to initiate a formal FDA pre-submission meeting for MST as a standalone indication. That regulatory conversation has to start somewhere, and a double-blind non-inferiority trial in Lancet Psychiatry is a credible place to begin it.
References
Dr. Leonardo Vando, MD is Principal Investigator of Psychiatry at Vando Medical Services.
